story of the week
Neoadjuvant Nivolumab vs Nivolumab Plus LAG-3 Inhibitor Relatlimab for Resectable Esophageal/Gastroesophageal Junction Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Nat. Med. 2024 Mar 19;[EPub Ahead of Print], RJ Kelly, BV Landon, AH Zaidi, D Singh, JV Canzoniero, A Balan, RK Hales, KR Voong, RJ Battafarano, BA Jobe, SC Yang, S Broderick, J Ha, KA Marrone, G Pereira, N Rao, A Borole, K Karaindrou, Z Belcaid, JR White, S Ke, AI Amjad, B Weksler, EJ Shin, E Thompson, KN Smith, DM Pardoll, C Hu, JL Feliciano, V Anagnostou, VK LamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.